miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells
- PMID: 24137413
- PMCID: PMC3789026
- DOI: 10.3892/ol.2013.1432
miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells
Abstract
Drug resistance is a major problem encountered in the treatment of ovarian cancer. Previous studies have demonstrated that in several types of cancer the overexpression of the multidrug resistance 1 (MDR1) gene is mainly associated with drug resistance. The present study aimed to investigate the role of miR-21 in the development of drug resistance in ovarian cancer cells. The expression levels of miR-21 in the ovarian cancer A2780 and A2780/taxol cell lines were detected by stem-loop real-time PCR. A2780 and A2780/taxol cells were transfected with mimics or inhibitors of miR-21 or negative control RNA. The expression levels of P-glycoprotein (P-gp) and hypoxia-inducible factor-1α (HIF-1α) proteins were assessed by western blot analysis. Drug sensitivity was analyzed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression levels of miR-21 and P-gp were upregulated to a greater extent in the paclitaxel-resistant ovarian cancer A2780/taxol cell line compared with the parental A2780 cell line. Transfection of A2780/taxol cells with inhibitors of miR-21 decreased the expression levels of the P-gp and HIF-1α proteins, and increased the sensitivity of the A2780/taxol cells to paclitaxel. The expression levels of P-gp were additionally increased; however, the sensitivity of the miR-21 mimic-treated A2780 cells to paclitaxel was decreased. miR-21 may be involved in the development of drug resistance and the regulation of MDR1/P-gp expression, at least in part, by targeting HIF-1α in ovarian cancer cells.
Keywords: hypoxia-inducible factor-1α; miR-21; ovarian cancer; paclitaxel resistance.
Figures





Similar articles
-
MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.Gynecol Oncol. 2010 Oct;119(1):125-30. doi: 10.1016/j.ygyno.2010.06.004. Epub 2010 Jul 10. Gynecol Oncol. 2010. PMID: 20624637
-
[Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):96-100. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17645840 Chinese.
-
[Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].Zhonghua Fu Chan Ke Za Zhi. 2010 May;45(5):372-5. Zhonghua Fu Chan Ke Za Zhi. 2010. PMID: 20646448 Chinese.
-
[Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2017 Feb 25;52(2):110-115. doi: 10.3760/cma.j.issn.0529-567X.2017.02.008. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 28253574 Chinese.
-
MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26396496 Free PMC article.
Cited by
-
Emerging role of microRNA-21 in cancer.Biomed Rep. 2016 Oct;5(4):395-402. doi: 10.3892/br.2016.747. Epub 2016 Aug 26. Biomed Rep. 2016. PMID: 27699004 Free PMC article.
-
Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1. J Transl Med. 2019. Retraction in: J Transl Med. 2022 Aug 4;20(1):351. doi: 10.1186/s12967-022-03560-y. PMID: 31171023 Free PMC article. Retracted.
-
Mechanisms of Taxane Resistance.Cancers (Basel). 2020 Nov 10;12(11):3323. doi: 10.3390/cancers12113323. Cancers (Basel). 2020. PMID: 33182737 Free PMC article. Review.
-
Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment.Front Immunol. 2022 Nov 10;13:1050917. doi: 10.3389/fimmu.2022.1050917. eCollection 2022. Front Immunol. 2022. PMID: 36439168 Free PMC article. Review.
-
The interactions of Fusobacterium nucleatum and Porphyromonas gingivalis with microRNAs: contributions to oral squamous cell carcinoma.Mol Biol Rep. 2025 Aug 12;52(1):821. doi: 10.1007/s11033-025-10926-0. Mol Biol Rep. 2025. PMID: 40794318
References
-
- Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol. 2011;32:1031–1047. - PubMed
-
- Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol. 1984;11:251–263. - PubMed
-
- Dai Z, Huang Y, Sadée W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004;4:1347–1356. - PubMed
-
- Fuchs J, Habild G, Leuschner I, Schweinitz DV, Haindl J, Knop E. Paclitaxel: an effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma. Med Pediatr Oncol. 1999;32:209–215. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous